Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Study of Single Agent Lenvatinib
- Status
- UNKNOWN
- Phase
- PHASE2
UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
- Status
- SUSPENDED
- Phase
- PHASE2
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor
- Status
- COMPLETED
- Phase
- PHASE1
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Lenvatinib in Second Line Endometrial Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
- Status
- COMPLETED
- Phase
- PHASE2
A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China
- Status
- COMPLETED
- Phase
- PHASE3
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Status
- COMPLETED
- Phase
- PHASE1
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1
The Drug Rediscovery Protocol (DRUP Trial)
- Status
- RECRUITING
- Phase
- PHASE2
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE1